INT81378

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 18
Total Number 24
Disease Relevance 7.87
Pain Relevance 7.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
immature T-cell 2
urine 2
plasma 1
spinal cord dorsal horns 1
Dpp4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dynorphin 42 99.92 Very High Very High Very High
Antihyperalgesic 4 99.80 Very High Very High Very High
Spinal cord 2 99.58 Very High Very High Very High
headache 6 99.34 Very High Very High Very High
Kappa opioid receptor 30 99.08 Very High Very High Very High
antagonist 6 98.92 Very High Very High Very High
Potency 6 98.48 Very High Very High Very High
Opioid 15 98.04 Very High Very High Very High
c fibre 2 97.42 Very High Very High Very High
substance P 13 97.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 903 99.84 Very High Very High Very High
Autism 21 99.28 Very High Very High Very High
Body Weight 66 96.40 Very High Very High Very High
Cardiovascular Disease 21 96.08 Very High Very High Very High
Hypoglycemia 51 95.60 Very High Very High Very High
Fibrosis 45 95.56 Very High Very High Very High
Hypertension 37 95.48 Very High Very High Very High
Weight Gain 41 94.88 High High
INFLAMMATION 145 93.64 High High
Hyperlipidemia 54 92.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences.
Negative_regulation (reduction) of peptidase IV
1) Confidence 0.59 Published 2003 Journal Physiol. Behav. Section Title Doc Link 14568317 Disease Relevance 0.25 Pain Relevance 0.21
The aims of this study were to (1) confirm the presence of opioid peptides in the urine of children with autism and (2) determine whether dipeptidyl peptidase IV (DPPIV/CD26) is defective in children with autism.
Spec (whether) Negative_regulation (defective) of DPPIV in urine associated with autism and opioid
2) Confidence 0.54 Published 2003 Journal Dev Med Child Neurol Section Abstract Doc Link 12578238 Disease Relevance 0.46 Pain Relevance 0.36
Others have observed similar results using FE 999011, an inhibitor of DPP IV, administrated orally in a dose of 10?
Negative_regulation (inhibitor) of DPP IV
3) Confidence 0.41 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 1.00 Pain Relevance 0.37
Therefore, it is well known that the inhibition of the serine protease DPP-IV in type 2 diabetes treatment prevents its activation of insulin-releasing peptide hormones.
Negative_regulation (inhibition) of DPP-IV associated with diabetes mellitus
4) Confidence 0.41 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.79 Pain Relevance 0.21
We concluded that carrageenan-induced C-fiber barrage (wind-up) may create ideal conditions for the de novo synthesis of endomorphin-2 in rat spinal cord dorsal horns if the DPP-IV enzyme is switched to the synthase functional mode by Ile-Pro-Ile.
Negative_regulation (switched) of DPP-IV enzyme in spinal cord dorsal horns associated with c fibre and spinal cord
5) Confidence 0.40 Published 2009 Journal Eur. J. Pharmacol. Section Abstract Doc Link 19695241 Disease Relevance 0.33 Pain Relevance 0.91
The aims of this study were to (1) confirm the presence of opioid peptides in the urine of children with autism and (2) determine whether dipeptidyl peptidase IV (DPPIV/CD26) is defective in children with autism.
Spec (whether) Negative_regulation (defective) of CD26 in urine associated with autism and opioid
6) Confidence 0.40 Published 2003 Journal Dev Med Child Neurol Section Abstract Doc Link 12578238 Disease Relevance 0.46 Pain Relevance 0.36
Three tested inhibitors, bacitracin, amastatin and puromycin, effectively inhibited the activities of APM, APN and DPP IV except for APB.
Negative_regulation (inhibited) of DPP IV
7) Confidence 0.39 Published 1999 Journal Life Sci. Section Abstract Doc Link 10210267 Disease Relevance 0 Pain Relevance 0.17
Intrathecally injected Ile-Pro-Ile, an inhibitor of membrane ectoenzyme dipeptidyl peptidase IV, is antihyperalgesic in rats by switching the enzyme from hydrolase to synthase functional mode to generate endomorphin 2.
Negative_regulation (inhibitor) of peptidase IV associated with antihyperalgesic
8) Confidence 0.35 Published 2009 Journal Eur. J. Pharmacol. Section Title Doc Link 19695241 Disease Relevance 0.37 Pain Relevance 0.58
The amount and activity of DPPIV in the plasma were quantified by an ELISA and DPPIV enzyme assay respectively; DPPIV was not found to be defective.
Negative_regulation (defective) of DPPIV in plasma
9) Confidence 0.35 Published 2003 Journal Dev Med Child Neurol Section Abstract Doc Link 12578238 Disease Relevance 0.46 Pain Relevance 0.36
By down-regulating DPPIV, dynorphin-A(1-17) may indirectly affect activity and/or specificity of natural substrates of DPPIV, such as substance P, RANTES, and endomorphins.
Negative_regulation (down-regulating) of DPPIV associated with dynorphin and substance p
10) Confidence 0.34 Published 2003 Journal Life Sci. Section Abstract Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.67
Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor.
Negative_regulation (down-regulated) of DPPIV in immature T-cell associated with dynorphin
11) Confidence 0.34 Published 2003 Journal Life Sci. Section Title Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.24
Collectively, cells of immature T cell line, R1.1 exert strong DPPIV enzyme activity, which could be down-regulated in the presence of dynorphin-A(1-17) by mechanism that presumably includes non-substrate inhibition.
Negative_regulation (down-regulated) of DPPIV in immature T cell associated with dynorphin
12) Confidence 0.34 Published 2003 Journal Life Sci. Section Abstract Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.70
Sitagliptin, an orally available DPP-IV inhibitor developed to be used as a once daily treatment for T2DM, has shown beneficial effects on glycaemic control, reducing HbA1c, and preventing hypoglycemia, as well as on islet mass and function, with no relevant adverse effects [16, 17].
Negative_regulation (inhibitor) of DPP-IV associated with hypoglycemia and diabetes mellitus
13) Confidence 0.30 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.44 Pain Relevance 0.05
Several reports have indicated that DPP-IV inhibitors are as antihyperglycaemic as any other oral antidiabetic drugs, with the additional benefit of not promoting hypoglycaemia and weight gain [45].
Negative_regulation (inhibitors) of DPP-IV associated with hypoglycemia and weight gain
14) Confidence 0.30 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.61 Pain Relevance 0.03
Future studies from us will estimate the effects of this DPP-IV inhibitor on the enzyme activity/expression, as well as on levels of GLP-1 and glucagon, in order to have a more detailed picture of how the incretins pathway is affected and its relative contribution for the effects of sitagliptin here reported.
Negative_regulation (inhibitor) of DPP-IV
15) Confidence 0.30 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.99 Pain Relevance 0
DPPIV down-regulation was resistant to bestatin and thiorphan, the inhibitors of two cell surface peptidases (APN and NEP, respectively) with potential of dynorphin-A(1-17) degradation, suggesting that the mechanism underlying the observed effect does not involve degradative products of dynorphin-A(1-17).
Negative_regulation (down-regulation) of DPPIV associated with dynorphin
16) Confidence 0.25 Published 2003 Journal Life Sci. Section Abstract Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.66
DPPIV down-regulation was also resistent to KOR antagonist, NBI, suggesting that the mechanism underlying the observed phenomenon involves neither cointernalization of KOR and DPPIV.
Negative_regulation (down-regulation) of DPPIV associated with antagonist and kappa opioid receptor
17) Confidence 0.25 Published 2003 Journal Life Sci. Section Abstract Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.73
Dynorphin-A(1-17) down-regulated DPPIV in a dose-dependent manner, with the potency similar to that of substance P, a known natural DPPIV substrate [Journal of Pharmacology and Experimental Therapeutics 260 (1992) 1257].
Negative_regulation (down-regulated) of DPPIV associated with dynorphin, substance p and potency
18) Confidence 0.25 Published 2003 Journal Life Sci. Section Abstract Doc Link 12738031 Disease Relevance 0 Pain Relevance 0.60
Vildagliptin (GalvusĀ®, LAF 237, Novartis) is an inhibitor of dipeptidyl peptidase 4 (DPP-4) that has been developed for the treatment of type 2 diabetes.
Negative_regulation (inhibitor) of DPP-4 associated with diabetes mellitus
19) Confidence 0.13 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899806 Disease Relevance 0.42 Pain Relevance 0
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Negative_regulation (inhibitor) of peptidase IV associated with headache
20) Confidence 0.12 Published 2008 Journal J Clin Pharmacol Section Title Doc Link 17986525 Disease Relevance 0.09 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox